| Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study | |
| Wu, Lijun; Xu Huji; Li Zhijun; Jian, Wu; Qian, Xing; Shi, Guixiu; Juan, Li; Xu, Liu; Li Xiaomei; Tan Wenfeng | |
| 刊名 | ARTHRITIS & RHEUMATOLOGY
 |
| 2018 | |
| 卷号 | 70 |
| ISSN号 | 2326-5191 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3513875 |
| 专题 | 吉林大学白求恩第三医院 |
| 推荐引用方式 GB/T 7714 | Wu, Lijun,Xu Huji,Li Zhijun,et al. Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study[J]. ARTHRITIS & RHEUMATOLOGY,2018,70. |
| APA | Wu, Lijun.,Xu Huji.,Li Zhijun.,Jian, Wu.,Qian, Xing.,...&Xiong, Wang.(2018).Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study.ARTHRITIS & RHEUMATOLOGY,70. |
| MLA | Wu, Lijun,et al."Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study".ARTHRITIS & RHEUMATOLOGY 70(2018). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论